Topic: value-based contracting
AstraZeneca is no stranger to value-based pricing agreements, even for heart drug Brilinta, but its latest is different.
CMS has pulled the plug on a plan to implement indication-specific pricing on Novartis' CAR-T drug Kymriah.
If Novartis thought public statements this week would silence questions about its $1.2 million contract with Michael Cohen, it was wrong.
AstraZeneca is looking to boost its key inhaler with two outcomes-based deals with regional insurers.
Despite lots of value-based talk, a new PwC survey finds the new payer contracting approach has yet to take off in a major way.